This isn’t a random scientist who got lucky.
Mariano Barbacid discovered the first human oncogene in 1982. He isolated H-RAS from bladder cancer cells and proved a single point mutation could trigger cancer. That finding launched the entire field of molecular oncology.
KRAS mutations cause 90% of pancreatic cancers. For 43 years, oncologists called KRAS “undruggable” because the protein had no obvious binding pocket. Barbacid spent the last decade using genetically engineered mice to systematically test every node in the KRAS signaling pathway, looking for combinations that would work without killing the patient.
The triple therapy blocks KRAS three ways at once: the main growth signal, the escape routes through EGFR and HER2, and the stress-response backup through STAT3. Cut the engine, seal the exits, disable the emergency system. Tumors vanished in mice and didn’t return for 200+ days after treatment stopped.
Pancreatic cancer has a 13% five-year survival rate. 8% for the ductal adenocarcinoma type this therapy targets. Most patients live one year after diagnosis.
The catch: this is preclinical. Human trials are 3+ years away. One of the drugs, RMC-6236, might get approved this year, but the full triple combination has regulatory hurdles.
Still. The man who discovered human oncogenes in 1982 may have just figured out how to eliminate the cancer those genes cause. That’s a 43-year arc from first principles to potential cure. Science rarely works this clean.
@Kodak You gotta be kidding me? Can’t tell if the CEO or marketing team is worse. It’s truly so bad out of both not sure I can declare a winner.
Really driving shareholder value here🙄
Diapers—and other personal care essentials—can feature customized images thanks to #Kodak’s advanced inkjet technology.
We help brands to deliver personalized products and boost efficiency, without compromising performance. Learn how: kodak.com/en/print/blog-…#KodakInnovation
We’re #Kodak.
When you partner with us, you’re working with one of the world’s leading industrial manufacturers in sectors ranging from #print to #pharma.
#KodakInnovation
@gadoliniumgal69@AlfredoARod@Kodak That’s all they list online although Jim said more in his Fox Business interview but nothing else listed on their website at all
@gadoliniumgal69@AlfredoARod@Kodak Ok, I’m going to let this one slide haha. 1 actual product in production is not great. The chemical profile is GREAT but got to execute on it
@gadoliniumgal69@AlfredoARod@Kodak Fair enough I just hope he’s pushing harder than anyone looking from the outside sees. From an outside perspective 1 or 2 interviews is NOT enough!
@gadoliniumgal69@AlfredoARod@Kodak It is but it’s not the future of the company. Continued declining sales in film are quarter after quarter. As a great investor I know you know this!
Kodak needs to make their investments over the past 5-6 years pay off. Many of us waiting and it’s not for the legacy business!
@Kodak Get it together over there. Stock is down over 30% from just months ago. CEO is not a leader and instead living in fear of his shame from getting the original loan pulled from the Covid days. Your PR team is an embarrassment. Care to explain print to pharma? Do better!
@Kodak You have had this on your website for literally months now. How about letting the public and investors know what other pharmaceutical products you’re producing. Jim said on his Fox Business interview there were a handful of other products. What are they? Do better with PR #KODK
Explore #KodakInnovation with our new pharma manufacturing facility tour, which highlights our Phosphate Buffered Saline manufacturing process.
See the technology and expertise behind our products in action: kodak.com/en/advanced-ma…#Kodak#Manufacturing
$BULL could be up 30% tomorrow just like our $KODK pick was the other week on a major crash day.
Inflection points are inflection points and they don't care what the rest of the market is doing.